Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

March 15, 2017
Kathleen N. Moore M.D.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Related Content:

SGO Annual Meeting on Women's CancerConferenceOvarian Cancer
HIPEC May Not Improve Outcomes for Recurrent Epithelial Ovarian Cancer
My Top 10 Hacks for Surviving with Cancer in the Infusion Room
FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer